Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy.
RNA therapy reverses the molecular damage in a rare inherited heart disease, opening a new treatment path for a high-risk condition.
Phosphoproteomic profiling of human phospholamban cardiomyopathy — a rare inherited cardiomyopathy with high risk of sudden cardiac death and progressive heart failure — identifies disease-specific molecular mechanisms not shared by other cardiomyopathy subtypes. Crucially, RNA therapy is demonstrated to reverse these phosphoproteomic signatures, providing translational validation for an emerging therapeutic approach in this high-unmet-need rare cardiac disease.
What the study was
- Study design
- Translational phosphoproteomic mechanistic study with therapeutic intervention
- Population
- Phospholamban (PLN) cardiomyopathy — rare autosomal dominant genetic cardiomyopathy
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Signal Transduction and Targeted Therapy
Why it surfaced
RNA therapy reversibility of phospholamban cardiomyopathy mechanisms is a meaningful translational advance for a rare cardiac disease with high sudden death risk and no approved disease-modifying therapy. Signal Transduct Target Ther publication (IF ~39) supports signal strength. NOVEL_TREATMENT flag auto-elevates to HIGH. Classification medium confidence — abstract not fully available at time of triage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.